gw786034
Chromophobe Renal Cell Carcinoma
Mayo ClinicPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Chromophobe Renal Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bms-907351 Bradley A. McGregor, MD | Phase 2 | B |
Nivolumab Bradley A. McGregor, MD | Phase 2 | CCC |
Ipilimumab Bradley A. McGregor, MD | Phase 2 | CCC |
Sorafenib National Cancer Institute (NCI) | Phase 1/2 | CCC |
nn3201 Novelty Nobility, Inc. | Phase 1 | CC |
View all 11 →
Same molecule, other indications
gw786034 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →